The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses.

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

The Phoenix facility supports vials, prefilled syringes, cartridges, and commercial lyophilization, backed by substantial ...

Telix contributes end-to-end radiopharma capabilities, including isotope selection, radiochemistry, scalable manufacturing, and a global distribution network tailored to short half-life radioisotopes.

Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human healthWill assist with listeri ...

Phase 1/2 RAINFOL™-01 data showed the combination ofrinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian c ...

SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s ...

FairJourney Bio (FJBio), a global antibody discovery contract research organization (CRO), today announced the opening of its advanced cryo-electron microscopy (cryo-EM) structural biology facility in ...

Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing ...

Voyager Therapeutics' anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD.

A new nanodisc-based platform lets scientists study viral proteins in a form that closely mimics real viruses, revealing how ...

I initiate coverage on Forte Biosciences stock at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.